Elisabetta has nearly 20 years drug discovery experience in the CNS and Oncology therapeutic areas, gained at GSK, Astex Pharmaceuticals and AstraZeneca. She contributed to the discovery of several preclinical and clinical candidates. Elisabetta is passionate Structure Based Drug Design, and developed novel rational design approaches such the use of 1D NMR free ligand conformational signatures to enhance Structure Activity and Structure Property relationships of small molecule inhibitors as well as PROTACs. Elisabetta is co-author of over 50 publications, patents, posters, and oral presentations and holds a Ph.D. in chemistry from the University of Lausanne, Switzerland. Elisabetta is currently section head of UK Oncology Medicinal Chemistry and Leader of the Oncology PROTAC platform.